Fresh Blood: 3 Stocks Ready to Rally Under New CEOs

In This Article:

In recent years, S&P 500 companies with new chief executive officers (CEOs) have become a regular occurrence. That’s because CEOs are moving on more quickly — both by choice and because of activist investors — and that means there are always interesting possibilities for stocks set to rally under new CEOs.

Equilar, a research company specializing in corporate leadership data, reported earlier this year that 62 of the Equilar 500 — America’s largest companies by revenue — announced CEO departures in 2022, up from 49 in 2021. The average tenure of CEOs leaving in 2022 was 7.7 years. Only 18 were in the top job for more than 10 years. 

In searching for stocks ready to rally under new CEOs, I thought about including Unilever (NYSE:UL). The U.K.-based consumer goods company will see incoming CEO Hein Schumacher take over in July with the difficult assignment of reinvigorating the company’s stock. Shares have lost 6.5% over the past five years compared to a 92% gain for Procter & Gamble (NYSE:PG) over the same period.  

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

However, because I want to focus on American-based companies, I’ve opted to pass on Unilever and go for S&P 500 companies instead. Below are three stocks ready to rally under new leadership.

Viatris (VTRS)

Viatris (VTRS) website page. Viatris.com logo on display screen
Viatris (VTRS) website page. Viatris.com logo on display screen

Source: Postmodern Studio / Shutterstock.com

Viatris (NASDAQ:VTRS) is the global healthcare company created by merging Pfizer’s (NYSE:PFE) Upjohn business and Mylan N.V. in November 2020. Pfizer shareholders got 0.124079 shares of Viatris for each share in the former parent. Viatris shares are down 37% since the merger.

On April 1, Scott Smith became the new CEO of Viatris, replacing Michael Goettler. Smith joined the company’s board in December 2022. He was a senior executive at Celgene for 10 years. The cancer and immunology drug company was acquired by Bristol-Myers Squibb (NYSE:BMY) in 2019. Among Smith’s accomplishments was developing and commercializing Otezla, a blockbuster drug to treat psoriasis. 

Smith is taking over Viatris as it transitions into a high-growth, high-cash-flow business. In 2023, the company expects to generate as much as $9 billion in cash from divestitures. In 2024, it expects to generate at least $2.3 billion in free cash flow annually, with 50% allocated toward dividends and share repurchases. 

Given Smith’s experience taking drugs from clinical trials through the commercialization stage, investors should expect a bright future. However, Wall Street has yet to buy into the company’s new strategic plan. Sometimes it takes a new CEO 12 months to get up to speed. In time, this appointment should reap dividends for Viatris shareholders.